A generic treatment of haemophilia, developed by Indian pharma gaint Dr Reddy’s Laboratories, is now available in the US market.
The company, which has a large presence in the UK, confirmed in a filing to the Bombay Stock Exchange that it has launched desmopressin acetate injection USP, 4 mcg/mL single-dose ampules in the US market.
The desmopressin acetate injection brand and generic market had US sales of approximately $20.9 (£16.9) million for the 12 months ending March 2020, according to IQVIA Health.
Dr Reddy’s Laboratories North America Generics CEO Marc Kikuchi said: “The launch of desmopressin injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company.”
SunGen Co-CEO Isaac Liu said: “We are pleased to be working with Dr Reddy’s for this launch. The launch of desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world.”
The drug is indicated for treatment of some types of haemophilia.
